within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB16_PeginterferonAlfacon2;

model PeginterferonAlfacon2
  extends Pharmacolibrary.Drugs.ATC.L.L03AB16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L03AB16</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Peginterferon alfacon-2 is a synthetic, pegylated form of interferon alpha used as an antiviral and immunomodulatory agent, primarily developed for the treatment of chronic hepatitis C infection. Its clinical use has largely been replaced by direct acting antivirals, but it was previously approved as part of combination therapy for hepatitis C.</p><h4>Pharmacokinetics</h4><p>No published literature reporting specific pharmacokinetic parameters such as clearance, volume of distribution, or absorption rate constants for peginterferon alfacon-2 in humans could be identified. Approximate estimates have been suggested based on available information for similar pegylated interferons.</p><h4>References</h4><ol><li><p>Hu, X, et al., &amp; Werneburg, B (2016). COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. <i>British journal of clinical pharmacology</i> 82(2) 380–388. DOI:<a href=\"https://doi.org/10.1111/bcp.12968\">10.1111/bcp.12968</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27060836/\">https://pubmed.ncbi.nlm.nih.gov/27060836</a></p></li><li><p>Simó, M, &amp; Iljicsov, A (2017). [Role of peginterferon-β-1a in the therapy of multiplex sclerosis]. <i>Ideggyogyaszati szemle</i> 70(11-12) 365–368. DOI:<a href=\"https://doi.org/10.18071/isz.70.0365\">10.18071/isz.70.0365</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29870644/\">https://pubmed.ncbi.nlm.nih.gov/29870644</a></p></li><li><p>Zhao, Y, et al., &amp; Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. <i>Med (New York, N.Y.)</i> 3(9) 612–621.e3. DOI:<a href=\"https://doi.org/10.1016/j.medj.2022.06.006\">10.1016/j.medj.2022.06.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35853458/\">https://pubmed.ncbi.nlm.nih.gov/35853458</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PeginterferonAlfacon2;
